Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KT-413 |
| Synonyms | |
| Therapy Description |
KT-413 degrades IRAK4, IKZF1 (Ikaros), and IKZF3 (Aiolos), potentially leading to tumor cell killing and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB118). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KT-413 | KT413|KT 413 | IRAK4 Inhibitor 8 | KT-413 degrades IRAK4, IKZF1 (Ikaros), and IKZF3 (Aiolos), potentially leading to tumor cell killing and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr LB118). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05233033 | Phase I | KT-413 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL | Completed | USA | GBR | 0 |